Navigation Links
Cervical Cancer Vaccine Approved for Use

Medicines Safety Authority Medsafe has approved the use of Gardasil, cervical cancer vaccine on Thursday. Several health professionals are calling for its use in a national// immunization program.

The vaccine is said to offer immunity against four strains of Human Papilloma Virus (HPV) which is a common sexually transmitted infection. Although HPV infects about half of sexually active adults sometime during their life, it is usually harmless. However, it can cause the development of abnormal cells in the cervix lining, which can turn cancerous.

Presently Gardasil is recommended for use from ages 9 to 26, before women become sexually active and is expected to eventually included in the national immunization schedule.

Still Medsafe says women will need to have regular pap smears because of limited protection, besides which it is not known how long the vaccine will last.

According to Biopharmaceutical company CSI Limited Gardasil will be available in New Zealand in September.

The vaccine will have to be included in the Ministry of Health's national immunization program before its nationwide implementation. However the next review of its schedule isn't due until 2008.

Dr Dynes McConnell, from the Royal Australasian College of Obstetricians and Gynaecologists has warned for the need for action before then. She says that New Zealand will face a risk of falling behind if the vaccine is not introduced on a national level within the next one to three years.

Each year around 180 women are diagnosed with cervical cancer in New Zealand and around 60 die from the disease.


'"/>




Page: 1

Related medicine news :

1. Virus Level could Predict Cervical Cancer Risk
2. Smallpox Vaccine May Help Fight Cervical Cancer
3. Obesity Increases Risk of Cervical Cancer
4. Reducing The Risk Of Cervical Cancer
5. Improving Fertility In Patients With Cervical Cancer
6. Vaccine for Cervical cancer
7. Cervical spinal injury patients may have more damage left undetected
8. Cervical Cancer Vaccine To Be Developed In India
9. Cervical Cancer Can Now Be Better Handled With Gene Silencing Therapy
10. Cervical Cancer Recurrence Risk Even After Removal Of Pre-Cancerous Cells
11. HPV Vaccines for Cervical Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about ... of skin cancer deaths. More than 10,000 people are expected to die of melanoma this ... it is the one of the most commonly diagnosed cancers in young women. A recent ...
(Date:4/29/2016)... ... , ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali is ... treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution to patients ... or both jaw bones. This surgery is performed to correct the alignment of the jaw. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... , April 27, 2016 ... Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor ... announced its sales for the first quarter ended March ... and the execution of its commercial strategy. ...
Breaking Medicine Technology: